Business
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
SHANGHAI & CAMBRIDGE, Mass., April 18, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class tre
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/13246db0794c2ca97bdd89d386dbf0b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bGwCRt4mcAvjQJRKKGEGSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0OA--/https://media.zenfs.com/en/business-wire.com/13246db0794c2ca97bdd89d386dbf0b2","width":480,"height":224}},"lazy":false},{"type":"text","content":"-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"-Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of ZL-1503, together with a favorable preclinical safety profile, supports potential for less frequent dosing than current biologics","length":232,"tagName":"p","attribs":{}},{"type":"text","content":"-Zai Lab initiated first-in-human Phase 1/1b studies of ZL-1503 in December 2025; clinical data expected in 2H 2026","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., April 18, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class treatment option for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases.","length":618,"tagName":"p"},{"type":"text","content":"IL-13 and IL-31 are key mediators in atopic disease. IL-13 promotes Type 2 inflammation and tissue changes, while IL-31 drives itch and amplifies local immune responses. Together, these cytokines perpetuate the itch-scratch-inflammation cycle that underlies the development and persistence of atopic dermatitis and related conditions, highlighting the need for therapies that effectively target both pathways simultaneously. ZL-1503 was engineered to...